Clinical trial
Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML)…
NCT00493181 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00493181 |
|---|---|
| Title | Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients |
| Official title | The Effect of Interleukin 11 on Thrombocytopenia Associated With Imatinib or Other Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myelogenous Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Interleukin-11 (IL-11 or Neumega) |
| Enrollment | 8 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2011 |
| Completion | Jan 1, 2011 |
| First posted | Jun 28, 2007 |
| Last update posted | Feb 20, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: